Shares of Targacept Inc. shot up a whopping 137 percent on news that TC-5214 hit its endpoints - bypassing expectations - in a Phase IIb study in major depressive disorder, giving the firm an edge in ongoing partnering discussions. (BioWorld Today) Read More
